Clinical Trials
10 trialsNCT07153497 2026-05-13
Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT07582172 2026-05-12
Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT07572929 2026-05-07
PREeMPT
Medical College of Wisconsin
Phase 2 Not yet recruiting
NCT07528417 2026-04-22
MYELO-CAN:ABX
University of Manitoba
Phase 2 Not yet recruiting
NCT07449286 2026-03-04
IFN-α in Relapse Prevention.
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT06987058 2025-09-24
ROVER-01
Ryvu Therapeutics SA
Phase 2 Not yet recruiting
NCT06900088 2025-03-28
Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT06598969 2024-09-19
TMLI-MA
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Phase 2 Not yet recruiting
NCT06602323 2024-09-19
TMLI-RI
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Phase 2 Not yet recruiting
NCT06050941 2024-03-05
Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS
First Affiliated Hospital of Zhejiang University
Phase 2 Not yet recruiting